NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$2.7b

Last Updated

2021/05/06 22:14 UTC

Data Sources

Company Financials +

Executive Summary

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. More Details


Snowflake Analysis

Undervalued with high growth potential.


Similar Companies

Share Price & News

How has Pacira BioSciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PCRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: PCRX's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

-1.5%

PCRX

1.5%

US Pharmaceuticals

-1.7%

US Market


1 Year Return

49.3%

PCRX

11.4%

US Pharmaceuticals

51.8%

US Market

Return vs Industry: PCRX exceeded the US Pharmaceuticals industry which returned 11.1% over the past year.

Return vs Market: PCRX underperformed the US Market which returned 52.8% over the past year.


Shareholder returns

PCRXIndustryMarket
7 Day-1.5%1.5%-1.7%
30 Day-6.3%2.9%1.5%
90 Day-14.6%1.5%3.1%
1 Year49.3%49.3%15.5%11.4%54.4%51.8%
3 Year84.0%84.0%37.5%26.6%63.0%52.8%
5 Year44.4%44.4%48.7%30.3%127.2%101.9%

Long-Term Price Volatility Vs. Market

How volatile is Pacira BioSciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Pacira BioSciences undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PCRX ($63.21) is trading below our estimate of fair value ($201.33)

Significantly Below Fair Value: PCRX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: PCRX is good value based on its PE Ratio (18.5x) compared to the US Pharmaceuticals industry average (23.6x).

PE vs Market: PCRX is good value based on its PE Ratio (18.5x) compared to the US market (20.4x).


Price to Earnings Growth Ratio

PEG Ratio: PCRX is good value based on its PEG Ratio (0.9x)


Price to Book Ratio

PB vs Industry: PCRX is overvalued based on its PB Ratio (4.3x) compared to the US Pharmaceuticals industry average (3.7x).


Future Growth

How is Pacira BioSciences forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

21.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PCRX's forecast earnings growth (21.2% per year) is above the savings rate (2%).

Earnings vs Market: PCRX's earnings (21.2% per year) are forecast to grow faster than the US market (15.7% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: PCRX's revenue (11.9% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: PCRX's revenue (11.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PCRX's Return on Equity is forecast to be high in 3 years time (22%)


Past Performance

How has Pacira BioSciences performed over the past 5 years?

73.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PCRX has a high level of non-cash earnings.

Growing Profit Margin: PCRX became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: PCRX has become profitable over the past 5 years, growing earnings by 73.7% per year.

Accelerating Growth: PCRX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: PCRX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.1%).


Return on Equity

High ROE: PCRX's Return on Equity (22.7%) is considered high.


Financial Health

How is Pacira BioSciences's financial position?


Financial Position Analysis

Short Term Liabilities: PCRX's short term assets ($720.2M) exceed its short term liabilities ($232.1M).

Long Term Liabilities: PCRX's short term assets ($720.2M) exceed its long term liabilities ($404.6M).


Debt to Equity History and Analysis

Debt Level: PCRX's debt to equity ratio (72.1%) is considered high.

Reducing Debt: PCRX's debt to equity ratio has increased from 46.5% to 72.1% over the past 5 years.

Debt Coverage: PCRX's debt is not well covered by operating cash flow (17.7%).

Interest Coverage: PCRX's interest payments on its debt are not well covered by EBIT (2.6x coverage).


Balance Sheet


Dividend

What is Pacira BioSciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PCRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PCRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PCRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PCRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PCRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.0yrs

Average management tenure


CEO

Dave Stack (70 yo)

13.5yrs

Tenure

US$9,344,282

Compensation

Mr. David M. Stack, also known as Dave, has been the Chief Executive Officer of Pacira Pharmaceuticals Inc. Since 2007, Mr. Stack has served as Chief Executive Officer and Chairman of Pacira BioSciences, I...


CEO Compensation Analysis

Compensation vs Market: Dave's total compensation ($USD9.34M) is above average for companies of similar size in the US market ($USD5.40M).

Compensation vs Earnings: Dave's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: PCRX's management team is seasoned and experienced (5 years average tenure).


Board Members

Experienced Board: PCRX's board of directors are considered experienced (7.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PCRX insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.5%.


Top Shareholders

Company Information

Pacira BioSciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Pacira BioSciences, Inc.
  • Ticker: PCRX
  • Exchange: NasdaqGS
  • Founded: 2006
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.726b
  • Shares outstanding: 44.01m
  • Website: https://www.pacira.com

Number of Employees


Location

  • Pacira BioSciences, Inc.
  • 5 Sylvan Way
  • Suite 300
  • Parsippany
  • New Jersey
  • 7054
  • United States

Listings


Biography

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/06 22:14
End of Day Share Price2021/05/06 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.